{"id":"NCT02997501","sponsor":"AstraZeneca","briefTitle":"T790M Plasma Testing Methodology Comparison and Clinical Validation","officialTitle":"Detect EGFR T790M Mutation in ctDNA of Chinese Advanced/Metastatic NSCLC Patients by Cobas, Super-ARMS, Digital PCR and NGS and Evaluate Clinical Outcomes of T790M Mutation Positive Patients Who Had AZD9291 Monotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-12-23","primaryCompletion":"2018-10-24","completion":"2018-10-24","firstPosted":"2016-12-20","resultsPosted":"2024-03-04","lastUpdate":"2024-03-04"},"enrollment":256,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"OTHER"},"conditions":["Lung Cancer"],"interventions":[{"type":"PROCEDURE","name":"T790M+ Testing","otherNames":[]},{"type":"PROCEDURE","name":"Baseline Visit Blood & Urine Testing","otherNames":[]},{"type":"PROCEDURE","name":"Baseline ECG","otherNames":[]},{"type":"PROCEDURE","name":"Visual Slit-Lamp Testing","otherNames":[]},{"type":"DRUG","name":"AZD9291 Dosing","otherNames":[]},{"type":"PROCEDURE","name":"Plasma AZD9291 testing","otherNames":[]}],"arms":[{"label":"AZD9291","type":"EXPERIMENTAL"}],"summary":"The aim of this study is to evaluate concordance of T790M mutation plasma testing between the Cobas test and each of other platforms: Super-ARMS, digital PCR or NGS. And to assess the efficacy of AZD9291 monotherapy by assessment of PFS in adult patients with advanced or metastatic NSCLC, who have received prior EGFR-tyrosine kinase inhibitor (TKI) therapy and are T790M mutation positive detected by any one of the four plasma testing platforms: Cobas/Super-ARMS/ digital PCR/NGS.","primaryOutcome":{"measure":"Concordance","timeFrame":"Up to 6 months","effectByArm":[{"arm":"Experimental","deltaMin":91.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":7,"countries":["China"]},"refs":{"pmids":[],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5160C00042&amp;attachmentIdentifier=00838057-bf4d-4a07-a48d-743b0f2b20d5&amp;fileName=D5160C00042_CSP.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5160C00042&amp;attachmentIdentifier=9e0016e3-e49b-4686-999d-b4a4e3ba74de&amp;fileName=D5160C00042_SAP.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5160C00042&amp;attachmentIdentifier=34d8d065-9a6f-4218-8fc1-539d1be96542&amp;fileName=D5160C00042-ADELOS-CSR.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":0},"commonTop":[]}}